Alzheimer's disease (AD) brain is defined by extracellular amyloid plaques and intracellular Tau aggregates that are believed to cause the neurodegeneration and devastating cognitive dysfunction of AD patients. AD therapies have focused primarily on intervening at brain amyloid levels; however, since both small molecule and immunotherapy approaches to reduce amyloid have yet to show cognitive improvement in AD patients, interest in new interventions that can provide additional benefits is on the rise. This review focuses on therapeutic approaches addressing metabolic risk factors and development of targets that reduce Tau pathology.